Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 209Stomach Neoplasms 37Neoplasm Metastasis 26Neoplasms 18HER2-positive Breast Cancer 14Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 10Brain Neoplasms 10Esophageal Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Urologic Neoplasms 3Lung Neoplasms 3Head and Neck Neoplasms 3HER2-positive Gastric Cancer 3Carcinoma 3Breast Cancer Metastatic 3Urinary Bladder Neoplasms 2Solid Tumors 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Melanoma 2HER2-positive Early Breast Cancer 2Cholangiocarcinoma 2Breast Diseases 2

Interventions

Gemcitabine 7Cisplatin 5pembrolizumab 4enfortumab vedotin 4Mitomycin 4Trastuzumab 3Pemetrexed 3Carboplatin 3dodecyl maltoside 2atezolizumab 2Sunitinib 2vinflunine 1valrubicin 1tucatinib 1palbociclib 1niraparib 1motexafin gadolinium 1cabozantinib 1avelumab 1apatorsen 1Water 1VMBP protocol 1Standard of Care 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Immunoglobulins, Intravenous 1Gels 1GSK-3326595 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Urologic Neoplasms × Trastuzumab × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT02006667 2015-02-11

A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Completed
13 enrolled 12 charts
Genitourinary

Urologic Neoplasms

NCT02013765 2014-09-25

A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Hoffmann-La Roche

Phase 2 Terminated
5 enrolled 12 charts
Genitourinary

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡